The brain structure of patients with recent-onset psychosis and depression can offer important biological insights into these illnesses and how they might develop.
In a new study published in Biological Psychiatry, researchers at the University of Birmingham show that it’s possible to identify patients most susceptible to poor outcomes by examining structural MRI scans of the brain.
By identifying these patients in the early stages of their illness, clinicians will be able to offer more targeted and effective treatments.
‘Currently, we diagnose most mental health disorders based on a patient’s history, symptoms, and clinical observations, rather than on biological information,’ says lead author Paris Alexandros Lalousis. ‘That means patients might have similar underlying biological mechanisms in their illness but different diagnoses. By understanding those mechanisms more fully, we can give clinicians better tools to use in planning treatments.’
The researchers used data from around 300 patients with recent-onset psychosis and recent-onset depression in the PRONIA study. PRONIA is a European Union-funded cohort study investigating prognostic tools for psychoses which is taking place across seven European research centres, including Birmingham.
The researchers used a machine-learning algorithm to assess data from patients’ brain scans and sort these into groups or clusters. Two clusters were identified based on the scans, each of which contained both patients with psychosis and patients with depression. Each cluster revealed distinctive characteristics which related strongly to their likelihood of recovery.
In the first cluster, lower volumes of grey matter – the darker tissue inside the brain involved in muscle control and functions such as memory, emotions, and decision-making – were associated with patients who went on to have poorer outcomes. In contrast, in the second group, higher levels of grey matter signalled patients who were more likely to recover well from their illness.
A second algorithm was then used to predict the patients’ condition nine months following the initial diagnosis. The researchers found a higher level of accuracy in predicting outcomes when using the biologically based clusters than traditional diagnostic systems.
Evidence also showed that patients in the cluster with lower volumes of grey matter in their brain scans might have higher levels of inflammation, poorer concentration, and other cognitive impairments previously associated with depression and schizophrenia.
Finally, the team tested the clusters in other large cohort studies in Germany and the US and was able to show that the same identified clusters could be used to predict patient outcomes.
‘While the PRONIA study contained people recently diagnosed with their illness, the other datasets we used contained people with chronic conditions,’ explains Lalousis. ‘We found that the longer the duration of illness, the more likely a patient would fit into the first cluster with lower grey matter volume. That really adds to the evidence that structural MRI scans may be able to offer useful diagnostic information to help guide targeted treatment decisions.’
The next step for the team is to validate the clusters in the clinic, gathering patient data in real-time, before planning larger-scale clinical trials.
